Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Dosage forms and strengths
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Product description Product information

Dosage forms and strengths

4 evidence topics · 1 source

Dosage form and strength

“Injection: 1.25 mg (0.05 mL of 25 mg/mL) colorless to light brown, opalescent solution for intravitreal injection in a single-dose vial.” (opens the prescribing information at this quote)

How supplied

“LYTENAVA (bevacizumab-vikg) injection is a colorless to light brown, opalescent solution. Each carton (NDC 82491-025-10) contains LYTENAVA 1.25 mg (0.05 mL of 25 mg/mL bevacizumab-vikg solution) in a single-dose glass vial with a BLUE CAP.” (opens the prescribing information at this quote)
“EACH CARTON IS FOR SINGLE-EYE USE ONLY.” (opens the prescribing information at this quote)

Storage and handling

“Store LYTENAVA refrigerated at 2oC to 8oC (36oF to 46oF) in the original carton until use to protect from light. DO NOT FREEZE.” (opens the prescribing information at this quote)
“Prior to use, the unopened glass vial of LYTENAVA may be kept at room temperature, 20oC to 25oC (68oF to 77oF), for up to 12 hours. Ensure the injection is given immediately after preparation of the dose.” (opens the prescribing information at this quote)

Composition

“LYTENAVA is supplied in a single-dose vial designed to deliver 0.05 mL of 25 mg/mL (1.25 mg) aqueous solution that also contains dibasic sodium phosphate (0.06 mg), monobasic sodium phosphate (0.29 mg), polysorbate 20 (0.02 mg), trehalose (2.71 mg), and Water for Injection. The pH is 6.” (opens the prescribing information at this quote)
“LYTENAVA (bevacizumab-vikg) injection is a sterile, colorless to light brown, opalescent solution for intravitreal use. LYTENAVA does not contain an anti-microbial preservative.” (opens the prescribing information at this quote)